INmune Bio Inc INMB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/17/24 EDT
10.85quote price arrow down-0.32 (-2.86%)
Volume
79,638
52 week range
6.50 - 14.74
Loading...
  • Open11.36
  • Day High11.36
  • Day Low10.76
  • Prev Close11.17
  • 52 Week High14.74
  • 52 Week High Date02/14/24
  • 52 Week Low6.50
  • 52 Week Low Date09/20/23

Key Stats

  • Market Cap214.639M
  • Shares Out19.78M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.92
  • YTD % Change-3.64

KEY STATS

  • Open11.36
  • Day High11.36
  • Day Low10.76
  • Prev Close11.17
  • 52 Week High14.74
  • 52 Week High Date02/14/24
  • 52 Week Low6.50
  • 52 Week Low Date09/20/23
  • Market Cap214.639M
  • Shares Out19.78M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.92
  • YTD % Change-3.64

RATIOS/PROFITABILITY

  • EPS (TTM)-1.92
  • P/E (TTM)-5.66
  • Fwd P/E (NTM)-4.25
  • EBITDA (TTM)-34.335M
  • ROE (TTM)-81.82%
  • Revenue (TTM)130,999.997
  • Gross Margin (TTM)-
  • Net Margin (TTM)-26,333.59%
  • Debt To Equity (MRQ)25.69%

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On INmune Bio Inc

 

Profile

MORE
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a...
Raymond Tesi M.D.
President, Chief Executive Officer, Director
David Moss
Chief Financial Officer
Address
225 Ne Mizner Blvd, Suite 640
Boca Raton, FL
33432
United States

Top Peers

SYMBOLLASTCHG%CHG
ABOS
Acumen Pharmaceuticals Inc
3.65-0.08-2.14%
LENZ
LENZ Therapeutics Inc
16.35-0.18-1.09%
CRVO
CervoMed Inc
24.09-0.27-1.11%
ZURA
Zura Bio Ltd
6.05+0.05+0.83%
TRVI
Trevi Therapeutics Inc
2.77-0.07-2.46%